Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2008-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMC.2007.10.076PMID 17988876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Molecular Connectivity Chi Indexes and Kappa Shape Indexes in Structure‐Property Modeling

  2007cited by this paper
• Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

  2007cited by this paper
• An Ultraefficient Affinity-Based High-Throughout Screening Process: Application to Bacterial Cell Wall Biosynthesis Enzyme MurF

  2006cited by this paper
• Structure‐based Optimization of MurF Inhibitors

  2006cited by this paper
• Utility of Muropeptide Ligase for Identification of Inhibitors of the Cell Wall Biosynthesis Enzyme MurF

  2006cited by this paper
• Selection of peptide inhibitors against the Pseudomonas aeruginosa MurD cell wall enzyme.

  2006cited by this paper
• Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening.

  2006cited by this paper
• Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.

  2005cited by this paper
• Novel target sites in bacteria for overcoming antibiotic resistance.

  2005cited by this paper
• Structure of MurF from Streptococcus pneumoniae co‐crystallized with a small molecule inhibitor exhibits interdomain closure

  2005cited by this paper
• Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography.

  2004cited by this paper
• Structure-activity relationships of novel potent MurF inhibitors.

  2004cited by this paper
• Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

  2003cited by this paper
• 2-Phenyl-5,6-dihydro-2H-thieno[3,2-c]pyrazol-3-ol derivatives as new inhibitors of bacterial cell wall biosynthesis.

  2003cited by this paper
• Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.

  2003cited by this paper
• LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites.

  2003cited by this paper
• Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

  2003cited by this paper
• Pitfalls in QSAR

  2003cited by this paper
• Structure and function of the Mur enzymes: development of novel inhibitors

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• The bacterial cell wall as a source of antibacterial targets

  2002cited by this paper
• Why do we need so many chemical similarity search methods?

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.

  2001cited by this paper
• Antimicrobial Resistance among Clinical Isolates ofStreptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995

  2001cited by this paper
• The cell wall and cell division gene cluster in the Mra operon of Pseudomonas aeruginosa: cloning, production, and purification of active enzymes.

  2001cited by this paper
• In vitro reconstruction of the biosynthetic pathway of peptidoglycan cytoplasmic precursor in Pseudomonas aeruginosa.

  2001cited by this paper
• A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors.

  2001cited by this paper
• Pharmacophore modeling and three-dimensional database searching for drug design using catalyst.

  2001cited by this paper
• Pharmacophore perception, development, and use in drug design

  2000cited by this paper
• Targeting cell wall synthesis and assembly in microbes: similarities and contrasts between bacteria and fungi.

  1999cited by this paper
• Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong

  1999cited by this paper
• Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity.

  1999cited by this paper
• Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins.

  1998cited by this paper
• Resolving the antibiotic paradox: progress in understanding drug resistance and development of new antibiotics.

  1998cited by this paper
• Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway.

  1998cited by this paper
• Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

  1998cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

  1997cited by this paper
• Identification of Common Functional Configurations Among Molecules

  1996cited by this paper
• The Statistical Sleuth

  1996cited by this paper
• Kinetic mechanism of the Escherichia coli UDPMurNAc-tripeptide D-alanyl-D-alanine-adding enzyme: use of a glutathione S-transferase fusion.

  1996cited by this paper
• Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.

  1995cited by this paper
• Poling: Promoting conformational variation

  1995cited by this paper
• Purification and characterization of the D-alanyl-D-alanine-adding enzyme from Escherichia coli.

  1990cited by this paper
• Liposidomycins: novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis.

  1985cited by this paper
• THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)

  1974cited by this paper

• Sustainable Synthesis of Medicinally Important Heterocycles.

  2025cites this paper
• Harnessing computational tools for drug discovery: An integrated computational approach to identify potential BACE-1 inhibitors.

  2025cites this paper
• The fall of the mycobacterial cell wall: interrogating peptidoglycan synthesis for novel anti-TB agents

  2024cites this paper
• Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand-based pharmacophores and biological screening

  2023cites this paper
• The Potential of Mur Enzymes as Targets for Antimicrobial Drug Discovery.

  2023cites this paper
• Molecular insight into the binding mode of thieno[3,2-c]pyrazol-3-ols with Streptococcus pneumoniae MurF enzyme by combined molecular modeling approach

  2022cites this paper
• Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches

  2022cites this paper
• A combination of heterogeneous catalysis and photocatalysis for the olefination of quinoxalin-2(1H)-ones with ketones in water: a green and efficient route to (Z)-enaminones

  2021cites this paper
• Chemical Synthesis of the Nucleoside Antibiotic Capuramycin

  2021cites this paper
• Design and Synthesis of 3,6-Disubstituted- and 2,3,6-Trisubstitutedquinoxalines: Docking and In Vitro Antimicrobial Study

  2020influential citation
• An explorative study on diarylquinoline-based inhibitor targeting Enterococcus faecium MurF

  2020cites this paper
• Facile Synthesis of Regioisomeric N‐ Alkyl Substituted 3‐Methylene‐3,4‐dihydroquinoxalin‐2(1 H )‐ones

  2019cites this paper
• QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor

  2019cites this paper
• Inhibition of dipeptidyl peptidase IV by fexofenadine: Virtual screening study

  2019cites this paper
• Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents.

  2019cites this paper
• Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.

  2018cites this paper
• Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads

  2017cites this paper
• Mur Ligase Inhibitors as Anti-bacterials: A Comprehensive Review.

  2017influential citation
• Discovery of novel potent nuclear factor kappa‐B inhibitors (IKK‐β) via extensive ligand‐based modeling and virtual screening

  2017cites this paper
• Switchable highly regioselective synthesis of 3,4-dihydroquinoxalin-2(1H)ones from o-phenylenediamines and aroylpyruvates

  2017cites this paper
• Insight into the structural requirements of thiophene-3-carbonitriles-based MurF inhibitors by 3D-QSAR, molecular docking and molecular dynamics study

  2017cites this paper
• Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.

  2016cites this paper
• Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation.

  2016cites this paper
• Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.

  2016cites this paper
• Pharmacophore Based Screening and Molecular Docking Study of PI3K Inhibitors

  2016cites this paper
• Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.

  2016cites this paper
• Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets

  2015cites this paper
• Identification of leads through in silico approaches utilizing benzylthio-1H-benzo[d]imidazol-1-yl acetic acid derivatives: A potent CRTh2 antagonist

  2015cites this paper
• Discovery of Check Point Kinase 1 (Chk1) Inhibitors as Potential Anticancer Agents Using Ligand-Based Modelling and Virtual Screening

  2015cites this paper
• Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators.

  2015cites this paper
• The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators

  2014cites this paper
• Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.

  2014cites this paper
• Inhibitors of the peptidoglycan biosynthesis enzymes MurA-F.

  2014cites this paper
• Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

  2014cites this paper
• Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis

  2014cites this paper
• Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors

  2014cites this paper
• Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors

  2013cites this paper
• Improved synthesis of capuramycin and its analogues.

  2013cites this paper
• Applications of Pharmacophore Mapping

  2013cites this paper
• Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors.

  2013cites this paper
• Crystallization and preliminary X-ray analysis of a UDP-MurNAc-tripeptide D-alanyl-D-alanine-adding enzyme (PaMurF) from Pseudomonas aeruginosa.

  2013cites this paper
• Ligand-based pharmacophore exploration and QSAR analysis of transition state analogues followed by in silico screening guide the discovery of new sub-micromolar β-secreatase inhibitors

  2013cites this paper
• New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study

  2013cites this paper
• Pharmacophore and QSAR Modeling of Endothelial Nitric Oxide Synthase Inhibitors and Subsequent Validation and In Silico Search for New Hits

  2012cites this paper
• Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.

  2012cites this paper
• Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors

  2012cites this paper
• Memory CD4+ T Cells: fate determination, positive feedback and plasticity

  2012cites this paper
• Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.

  2012cites this paper
• DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study.

  2012cites this paper
• Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymycins.

  2012cites this paper
• Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.

  2011cites this paper
• Discovery of new β‐D‐galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cites this paper
• Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.

  2011cites this paper
• Discovery of new β-d-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cites this paper
• Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.

  2011cites this paper
• Discovery of New Antifungal Leads via Pharmacophore Modeling and QSAR Analysis of Fungal N‐Myristoyl Transferase Inhibitors Followed by In Silico Screening

  2011cites this paper
• Determination of the antibiofilm, antiadhesive, and anti-MRSA activities of seven Salvia species

  2010cites this paper
• Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.

  2010influential citation
• Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.

  2010cites this paper
• Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.

  2010cites this paper
• 8.13 – Enzymology of Bacterial Resistance

  2010cites this paper
• Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.

  2010cites this paper
• Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90α Inhibitors

  2010cites this paper
• Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.

  2010cites this paper
• Concise synthesis of capuramycin.

  2009cites this paper
• Computational Intelligence Methods for Docking Scores

  2009cites this paper
• Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and Shape-Complemented in Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors

  2009cites this paper
• Discovery of novel benzene 1,3-dicarboxylic acid inhibitors of bacterial MurD and MurE ligases by structure-based virtual screening approach.

  2009cites this paper
• Discovery of DPP IV Inhibitors by Pharmacophore Modeling and QSAR Analysis followed by in silico Screening

  2008cites this paper
• Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.

  2008cites this paper